Exact Sciences CORP DEFA14A Filing
Ticker: EXAS · Form: DEFA14A · Filed: Nov 26, 2025 · CIK: 1124140
| Field | Detail |
|---|---|
| Company | Exact Sciences CORP (EXAS) |
| Form Type | DEFA14A |
| Filed Date | Nov 26, 2025 |
| Pages | 12 |
| Reading Time | 14 min |
| Key Dollar Amounts | $105 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a DEFA14A filing submitted by Exact Sciences CORP (ticker: EXAS) to the SEC on Nov 26, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $105 (ccount will be converted to cash at the $105 per share price upon the close, in acco).
How long is this filing?
Exact Sciences CORP's DEFA14A filing is 12 pages with approximately 3,595 words. Estimated reading time is 14 minutes.
Where can I view the full DEFA14A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 3,595 words · 14 min read · ~12 pages · Grade level 13.3 · Accepted 2025-11-26 16:01:04
Key Financial Figures
- $105 — ccount will be converted to cash at the $105 per share price upon the close, in acco
Filing Documents
- d935160ddefa14a.htm (DEFA14A) — 57KB
- 0001193125-25-300474.txt ( ) — 58KB
Forward-Looking Statements
Forward-Looking Statements This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott Laboratories. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the possible inability of the parties to consummate the proposed transaction on a timely basis or at all; the possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including necessary regulatory approvals and the requisite vote by Exact Sciences' stockholders, on a timely basis or at all; the possible occurrence of any event, change or other circumstance that could give rise to the termination of the parties' definitive agreement for the proposed transaction (the "Merger Agreement"); the risk that the Merger Agreement may be terminated in circumstances that require Exact Sciences to pay a termination fee; the possibility that competing offers may be made; the potential adverse impact on Exact Sciences of contractual restrictions under the Merger Agreement that limit Exact Sciences' ability to pursue business opportunities or strategic transactions; risks relating to significant transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated; potential adverse effects of the announcement or pendency of the proposed transaction, or any failure to complete the proposed transaction, on the market price of Exact Sciences' common stock or on the ability of Exact Sciences to develop and maintain relationships with its personnel (including Exact Sciences' ability to attract and retain highly qualified management and other scientific personnel) and customers, suppliers and others with whom it does business o